Results 211 to 220 of about 75,591 (303)

Charting the decline of the fourth wave: US overdose deaths by race, ethnicity and substance involvement

Addiction, EarlyView.
Abstract Aims To characterize decreases in overdose death rates in the United States (US) between 2023 and 2024 by race/ethnicity, and substance involvement. Design Population‐based study of national death records accessed via the Centers for Disease Control and Prevention (CDC) Wide‐ranging ONline Data for Epidemiologic Research (WONDER) platform ...
Joseph R. Friedman, Joseph J. Palamar, Daniel Ciccarone, Tommi L. Gaines, Annick Borquez, Chelsea L. Shover, Steffanie A. Strathdee   +6 more
wiley   +1 more source

Post-Hospital Access to Preferred and High-Quality Skilled Nursing Facilities for Patients With Opioid Use Disorder. [PDF]

Health Serv Res
Benheim TS, Rahman M, Zullo AR, Ritter AZ, Kimmel SD, Dow PM.   +5 more
europepmc   +1 more source

The association between naloxone distribution, buprenorphine treatment and retention and incident high‐risk opioid prescribing with opioid overdose death in Kentucky, Massachusetts, New York and Ohio, United States: An exploratory community‐level cohort study of data from the HEALing Communities Study

Addiction, EarlyView.
Abstract Aim We evaluated whether community‐level naloxone distribution, medication for opioid use disorder treatment and retention and incident high‐risk opioid prescribing rates were associated with opioid overdose death rates. Design Observational cohort conducted using 2019 to 2023 community‐level data as an exploratory analysis of the HEALing ...
Alexander Y. Walley, Debbie M. Cheng, Nathan Vandergrift, Marc Larochelle, JaNae Holloway, Jennifer L. Brown, Redonna Chandler, Laura C. Fanucchi, Daniel J. Feaster, Patricia R. Freeman, Timothy Hunt, Michelle R. Lofwall, Hannah K. Knudsen, Edward V. Nunes, Emmanuel Oga, Douglas R. Oyler, Jeffrey H. Samet, Jennifer Villani, Sharon L. Walsh, T. John Winhusen   +19 more
wiley   +1 more source

Emergency Department-Initiated Buprenorphine for Opioid Use Disorder: A Randomized Clinical Trial. [PDF]

JAMA
D'Onofrio G, Herring AA, Hawk KF, Perrone J, Cowan E, McCormack RP, Dziura J, Matthews AG, Pantalon MV, Owens P, Martel S, Coupet E, Lofwall MR, Walsh SL, Edelman EJ, Carpenter JE, Strout TD, Baumann MR, Anderson E, Barrett TW, Dorey A, Taillac P, Cochran G, Crandall CS, Wilson J, Manteuffel J, Cole JB, Whiteside LK, Jones C, Samuels E, Huntley K, Fiellin DA, ED INNOVATION Investigators.   +32 more
europepmc   +1 more source

Characteristics of deaths due to drug‐related causes among individuals recently released from prison in the United Kingdom, 1997–2025

Addiction, EarlyView.
Abstract Background and aims There has been an extensive literature describing the elevated risk of drug‐related death following an individual's release from prison; however, few previous studies have reported nationally representative samples or provided granular detail as to which individual drugs were deemed implicated in death.
Emmert Roberts, John Strang, Caroline Copeland   +2 more
wiley   +1 more source

Opioid Use Disorder Care Presentations After High-deductible Health Plan Enrollment. [PDF]

J Addict Med
Shuey B, Zhang F, Argetsinger S, Costa R, Wen H, Wharam JF.   +5 more
europepmc   +1 more source

Change of substance‐related hospitalisation in adolescents after cannabis legalisation in Thailand in 2022

Addiction, EarlyView.
Abstract Background and aims On 9 June 2022, Thailand changed its cannabis legislation, expanding access to individuals aged >18 years. Evidence suggests that such changes could increase the risk of cannabis use and related harms, and could influence patterns of use of other substances among adolescents.
Sirada Puetpaiboon, Songyos Rajborirug, Vorthunju Nakhonsri, Chumpol Ngamphiw, Peerapat Khunkham, Sissades Tongsima, Watcharapot Janpoung, Virasakdi Chongsuvivatwong   +7 more
wiley   +1 more source

Do No Harm? Rethinking Urine Drug Screens in Treatment of Opioid Use Disorder. [PDF]

J Am Board Fam Med
Beliveau C, Baca-Atlas M.
europepmc   +1 more source

Comparative effectiveness of alternative times to opioid agonist treatment taper initiation on taper completion and all‐cause mortality among people with opioid use disorder: A retrospective population‐based target trial emulation study in British Columbia, Canada, 2010–2020

Addiction, EarlyView.
Abstract Background and aims Opioid use disorder (OUD) treatment guidelines worldwide recommend opioid agonist treatment (OAT) as a long‐term, potentially indefinite treatment for managing OUD. However, many individuals express a strong interest in eventually tapering fully off treatment.
Ruyu Yan, Jeong Eun Min, Megan Kurz, Shaun R. Seaman, Paxton Bach, Sander Greenland, Paul Gustafson, Mohammad Ehsanul Karim, Lawrence McCandless, Robert William Platt, Uwe Siebert, María Eugenia Socías, Hui Xie, Bohdan Nosyk   +13 more
wiley   +1 more source

Evaluating the optimal duration of medication treatment for opioid use disorder. [PDF]

Addiction
Hayes CJ, Raciborski RA, Acharya M, Noor NB, Nunes EV, Winhusen TJ.   +5 more
europepmc   +1 more source